Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Progressive Fibrosing ILD
NCT06440746Phase 3Recruiting
- Sponsor
- R-Pharm
- Start
- Aug 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of olokizumab in interstitial lung disease (ILD), sponsored by R-Pharm. Started Aug 2023; status: recruiting.
02
Drugs
olokizumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06440746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440746.